Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Set On Competing With Merck And Roche, Dr Reddy's Labs Pins Hopes On CETP Drug

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Despite the odds against developing a robust pipeline of innovative drugs, Kallam Anji Reddy, founder and chairman of the $1.36 billion Dr. Reddy's Labs, refuses to give up the chase to discover new drugs

You may also be interested in...



INTERVIEW: Dr. Reddy’s CEO On Move From Curing Diseases To Managing Health (Part 2 of 2)

G.V. Prasad, the CEO of Dr. Reddy’s Laboratories Ltd. is known for his big picture views. In this second part of a freewheeling interview, Prasad shared his thoughts on diverse subjects, most striking of all was the vision to shift gears from curing diseases to managing health.

American Heart Association Scientific Sessions, In Brief

CETP inhibitors gaining traction: Data presented at the American Heart Association's 2009 Scientific Sessions Nov. 14-18 in Orlando, Fla., show that the remaining cholesteryl ester transfer inhibitors - Roche's dalcetrapib and Merck's anacetrapib (MK-0859) - are on track. The CETP class was cast into shadow after Pfizer discontinued work on its potential juggernaut torcetrapib in December 2006 due to elevated blood pressure and increased cardiovascular mortality (1"The Pink Sheet," Dec. 11, 2006). But Roche and Merck have concentrated on learning from the torcetrapib experience and a growing body of evidence shows that dalcetrapib and anacetrapib are sufficiently different from torcetrapib to avoid the negative side effects while still offering the benefit of raising HDL cholesterol (2"The Pink Sheet," Jan. 5, 2009). At AHA, Roche revealed the dal-OUTCOMES study is on track, with 9,000 of the total 15,600 patients enrolled in the morbidity/mortality trial. Roche also announced the initiation of a new, 24-month Phase III clinical trial, dal-PLAQUE 2, to determine the impact of dalcetrapib on artherosclerotic disease progression in more than 900 patients as measured by ultrasound imaging techniques (both intima media thickness and intravenous ultrasound). Additionally, the firm presented preclinical data on dalcetrapib's molecular structure and interaction with CETP to bolster previously reported studies showing the drug's specific mechanism of action. Merck released Phase IIb data showing nearly 600 patients with high cholesterol treated with anacetrapib alone or in combination with atorvastatin showed persistent lipid lowering in the higher-dose arms of the treatment groups. The results strengthen findings originally reported in February 2009 in the American Heart Journal. Data from Merck's Phase III DEFINE trial of anacetrapib are expected in 2010

Dr. Reddy's To Close Atlanta Facility In Reorganization; Focus On Key Markets To Drive Revenues To $3 Billion By 2013

MUMBAI - Need for optimization of infrastructure and resources, falling productivity and spiraling cost of discovery research has led Dr. Reddy's Labs, one of India's largest drug companies, to integrate its drug discovery operations with Aurigene - a partnership-based discovery biotech unit that it owns in Bangalore

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel